C57BL/6J female mice were injected i.p. with 500 ng recombinant murine IL-33 (Biolegend) in 100 μl PBS or PBS alone, once daily for 4 consecutive days. Animals were culled on day 5 and tissues harvested for ILC2 purification by FACS.
Recombinant murine il 33
Manufactured by BioLegend
Sourced in United States
Recombinant murine IL-33 is a protein that belongs to the interleukin-1 (IL-1) family of cytokines. It is produced in E. coli and purified using standard biochemical techniques.
Automatically generated - may contain errors
Lab products found in correlation
Facscalibur cytometer, by BD (1 mentions)
Mab17061, by R&D Systems (1 mentions)
Mab417, by R&D Systems (1 mentions)
Necrostatin 1, by AbMole (1 mentions)
Z vad fmk, by Apexbio (1 mentions)
Recombinant mouse il 2, by Thermo Fisher Scientific (1 mentions)
Recombinant murine amphiregulin, by R&D Systems (1 mentions)
Recombinant murine il 10, by Thermo Fisher Scientific (1 mentions)
Amd3100, by Bio-Techne (1 mentions)
Wild type c57bl 6j mice, by Jackson ImmunoResearch (1 mentions)
C57bl 6j mice, by Jackson ImmunoResearch (1 mentions)
Il 33, by Thermo Fisher Scientific (1 mentions)
Protein g dynabead, by Thermo Fisher Scientific (1 mentions)
Sds page gel, by Thermo Fisher Scientific (1 mentions)
Dynabeads, by BioLegend (1 mentions)
Goat anti rabbit igg secondary antibody hrp, by Thermo Fisher Scientific (1 mentions)
Westernsure premium reagent, by LI COR (1 mentions)
Ril 7, by Thermo Fisher Scientific (1 mentions)
Magpix multiplexing system, by DiaSorin (1 mentions)
Ionomycin, by Merck Group (1 mentions)
19 protocols using recombinant murine il 33
1
IL-33-Induced ILC2 Purification
2
IL-33 Treatment in NZB/W F1 Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NZB/W F1 mice were bred from the parental strains, NZW and NZB mice at the animal facility, Faculty of Medicine, HKU. Female mice were randomly sorted into two groups and given intraperitoneal (i.p.) injections with 100 μL of 0.4 μg recombinant murine IL-33 (BioLegend, San Diego, CA, USA) or only phosphate-buffered saline (PBS). Treatments were performed twice per week, for five consecutive weeks, from six weeks of age. The treatment protocol was based on an earlier study of IL-33 in colitis model [17 (link)].
3
Malaria Infection and Cerebral Malaria Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
C57BL/6 red blood cells infected with Plasmodium berghei ANKA parasites expressing a green fluorescent protein (PbA GFPcon 259cl2, MRA-865, deposited by CJ Janse and AP Waters) were stored in liquid nitrogen and thawed and passed into wild-type mice that served as parasite donor. All mice, unless otherwise stated, were inoculated intravenously (i.v.) into the tail vein with 1×104 parasitized red blood cells (pRBC). Parasitemia was monitored daily (from day 4) by flow cytometry using the FL3 channel (PbA-GFP) and TER-119 APC (erythrocytes) in a BD FACScalibur cytometer (BD Biosciences). Clinical score was assessed using the following clinical scale: 1 = no signs; 2 = ruffled fur and/or abnormal posture; 3 = lethargy; 4 = reduced responsiveness to stimulation and/or ataxia and/or respiratory distress/hyperventilation; and 5 = prostration and/or paralysis and/or convulsions. All animal that reachs stage 4 developped ECM. Recombinant murine IL-33 (Biolegend) was injected intraperitoneally (0.2 μg/mouse/200 μl) daily, routinely from the beginning of infection (day 0). As a control for IL-33 effects, non-infected (NI) mice also received IL-33 for 5 consecutive days. For some experiments, mice were administered with anti-Siglec F (MAB17061, R&D Systems, 50 μg daily) or anti-IL-10 (MAB417, R&D Systems, 40 μg daily) or appropriate isotype control Abs.
4
Modulation of IL-2 Complex-Induced Responses
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
IL-2/α-IL-2 complexes (IL-2c) were prepared as follows. About 1 ug recombinant mouse IL-2 (Peprotech) was mixed with 5 ug α-IL-2 (Bioxcell, clone JES6-1) and incubated at 37 °C for 30 min. Mice were injected intraperitoneally (i.p.) with IL-2c for 3 consecutive days and sacrificed for analysis 48 h later.
In the IL-2c treatment experiment, for blockade of cell death in vivo, 10 mg/kg Z-VAD-FMK (Apexbio Technology) and 5 mg/kg Necrostatin-1 (Abmole) or DMSO in PBS were injected i.p. daily for 5 days. In the IL-2c treatment experiment, for blockade of FASL in vivo, 400 ug IgG (Bioxcell) or α-FASL (Bioxcell) in PBS was injected i.p. on day −1, 1, and 3, and mice were sacrificed for analysis on day 5.
For IL-33 treatment in vivo, mice were i.p. injected with 500 ng recombinant murine IL-33 (BioLegend) or PBS for 4 consecutive days and sacrificed for analysis on day 5.
In the IL-2c treatment experiment, for blockade of cell death in vivo, 10 mg/kg Z-VAD-FMK (Apexbio Technology) and 5 mg/kg Necrostatin-1 (Abmole) or DMSO in PBS were injected i.p. daily for 5 days. In the IL-2c treatment experiment, for blockade of FASL in vivo, 400 ug IgG (Bioxcell) or α-FASL (Bioxcell) in PBS was injected i.p. on day −1, 1, and 3, and mice were sacrificed for analysis on day 5.
For IL-33 treatment in vivo, mice were i.p. injected with 500 ng recombinant murine IL-33 (BioLegend) or PBS for 4 consecutive days and sacrificed for analysis on day 5.
5
Intranasal IL-33 Enhances Pneumonia Resistance
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In some experiments, mice were treated intranasally with 1 or 3 μg recombinant murine IL-33 (BioLegend) in a volume of 40 μl per mouse or PBS for 4 consecutive days (once a day). On day 6 after first IL-33 treatment, mice were inoculation with a sub-lethal dose of L. pneumophila. Mice were killed on day 2-post infection, and bacterial loads analysed. FACS analysis was performed on day 7-post the first inoculation of IL-33 to identify M2 macrophage populations. Cytokine analysis was performed on day 8 after IL-33 administration17 (link). In another set of experiment, mice were treated with recombinant murine sST2, which was produced at the VIB Protein Service Facility, VIB Inflammation Research Center (Ghent, Belgium) and kindly provided by Dr Rudi Beyaert. Mice were injected subcutaneously with 100 μg of sST2 in a volume of 200 μl per mouse or PBS on days 1.5, 3, 5, 7, 9, 11 and 13 after CLP (once a day). At fifteenth day after CLP, surviving mice were challenged intranasally with a sublethal dose of L. pneumophila.
6
Murine IL-33 Injection Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Recombinant murine IL-33 (1.0 μg/mouse) in PBS (Biolegend, 580508) was intraperitoneally injected into WT or il1rl1−/− mice for six consecutive days and analyzed 24 h after the last injection. Control mice were injected intraperitoneally with PBS.
7
Murine IL-33 Induced Inflammation
8
Cytokine Delivery Protocol for Murine Studies
9
Sepsis Induction and Modulation in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Male C57BL/6 J wild-type (WT) mice (6-week-old) and aging C57BL/6 J mice (18-month-old) (The Jackson Laboratories, Bar Harbor, ME), IL-33-deficient (Il33−/−) and ST2-deficient (St2−/−) mice were maintained at the Animal Facility of the University of Pittsburgh School of Medicine. All animal experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committees of University of Pittsburgh and VA Pittsburgh Healthcare System.
CLP was conducted to induced mid-grade sepsis as described previously (Rittirsch et al. 2009 (link)). In some experiments, mice were injected intravenously (i.v.) with AMD3100 (3.2 mg/kg B.W. in 100 μl PBS, Tocris Bioscience, Minneapolis, MN) or intraperitoneally (i.p.) with sST2 (0.4 mg/kg B.W. in 200 μl PBS, R&D system, Minneapolis, MN) at 30 min prior to CLP procedure. Some groups of mice were also treated i.v. with recombinant murine IL-33 (40 µg/kg B.W. in 200 μl of PBS, BioLegend, San Diego, CA).
CLP was conducted to induced mid-grade sepsis as described previously (Rittirsch et al. 2009 (link)). In some experiments, mice were injected intravenously (i.v.) with AMD3100 (3.2 mg/kg B.W. in 100 μl PBS, Tocris Bioscience, Minneapolis, MN) or intraperitoneally (i.p.) with sST2 (0.4 mg/kg B.W. in 200 μl PBS, R&D system, Minneapolis, MN) at 30 min prior to CLP procedure. Some groups of mice were also treated i.v. with recombinant murine IL-33 (40 µg/kg B.W. in 200 μl of PBS, BioLegend, San Diego, CA).
10
Investigating IL-33 Effects on Adipose Tissue
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!